Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives European approval for cancer drug Tagrisso

AstraZeneca receives European approval for cancer drug Tagrisso

4th February 2016

AstraZeneca has announced that its new cancer therapy Tagrisso has been conditionally approved by the European Commission.

The once-daily tablets have been ratified for use in the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Eligibility for treatment with the drug is dependent on mutation status, to be determined through a validated diagnostic test based on a tumour tissue sample or plasma, as Tagrisso is part of a new class of personalised medicines optimised to aid specific patients.

Clinical study data showing the progression-free survival benefits of the drug was used to support the approval of the new drug.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We are now building on our understanding of the clinical activity of osimertinib to explore its full potential in patients with EGFRm lung cancer in multiple treatment settings."

The therapy has been available in the UK under the Early Access to Medicines Scheme since December 2015.ADNFCR-8000103-ID-801811813-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.